Home
HEALTH CARE
Allergy and hay fever
Antineoplastic and immunomodulating agents
Circulatory system
Colds and flu
Dermatology
Digestive system
Eyes
For diabetics
Homeopathy
Musculoskeletal system
Non-sex hormones
Nutrikosmetics
Pain
Preparations for the treatment of infections
Sex and contraception
The immune system
The nervous system
Urogenital tract
Vitamins and minerals
HEALTHY LIFESTYLE
For athletes
Healthy food
Slimming
HYGIENE
Disinfection
Ear hygiene
Hot and cold compresses
Intimate hygiene
Laundry products
Oral hygiene
Slices and sticks
Urinary incontinence
COSMETICS
Cosmetic articles
For eyelashes and eyebrows
For face
For hair
For hands and nails
For the body
Soap
Sunbathing
To the feet
To the mouth
FOR HIM
Cosmetics for men
Health
PREGNANCY AND MOTHERHOOD
Accessories
Cosmetics for pregnant women
Health in pregnancy
Supporting fertility
CHILD
Baby nutrition
Child health
Cosmetics for children
Hygiene items for children
Oral hygiene (for children)
Scrolling
HEALTH CARE
Zeffix 100mg 28 tablets — Made in Poland — Free Delivery
Zeffix 100mg 28 tablets — Made in Poland — Free Delivery
Brand:
GlaxoSmithKline
Product Code:
Zeffix
Availability:
In Stock
$72.70
Add to Cart
Description
Product d
escription
Zeffix tablets are indicated for chronic viral hepatitis B in adults against the background of hepatitis B virus replication.
Compound
Active substance: lamivudine;
1 tablet contains 100 mg of lamivudine;
Excipients: microcrystalline cellulose, sodium starch (type A), magnesium stearate, shell YS-1R-17307-A (hypromellose, titanium dioxide (E 171), synthetic yellow iron oxide (E172), synthetic red iron oxide (E172), macrogol 400, polysorbate 80).
Contraindications
Zeffix is contraindicated in case of hypersensitivity to lamivudine or other components of the preparation.
Mode of application
The recommended dose of Zeffix is 100 mg once a day.
Patients who cannot swallow tablets are advised to use Zeffix in the form of an oral solution.
The preparation should be taken with or without food. Swallow the tablet whole with water.
During treatment, it is imperative to monitor patient compliance with the therapy regimen.
Discontinuation of Zeffix treatment is possible for patients with normal immunity indicators after achieving seroconversion of HBeAg and HBsAg. The question of discontinuation of treatment should also be considered in case of ineffectiveness of therapy is manifested by a relapse of hepatitis.
After discontinuation of Zeffix therapy, dynamic monitoring of patients is recommended in order to timely detect a possible relapse of the disease.
It is not recommended to discontinue treatment in patients with decompensated stage of liver disease. Currently, there are limited data on the maintenance of seroconversion for a long time after discontinuation of Zeffix therapy.
Application features
Pregnant
Zeffix can be used during pregnancy if clinically needed.
Children
Not recommended for use.
Drivers
Carefully.
Overdose
Information on the consequences of acute overdose in humans is limited. Lethal cases were not recorded, the condition of all patients returned to normal. There were no specific signs and symptoms of overdose.
In case of overdose, it is recommended to monitor the patient's condition and carry out standard supportive therapy. Given that lamivudine is dialyzed, continuous hemodialysis can be used, but no specific studies have been conducted.
Side effects
The most common: malaise and fatigue, respiratory tract infections, discomfort in the throat and tonsils, headache, abdominal discomfort and pain, nausea, vomiting and diarrhea.
Interaction
Due to its similarities, Zeffix should not be administered concurrently with other cytidine analogs such as emtricitabine. In addition, Zeffix should not be used in conjunction with any other medicinal product containing lamivudine.
Storage conditions
Store at a temperature not exceeding 30 ° C.
Keep out of the reach of children.
Shelf life is 3 years.
0 reviews
There are no reviews for this product.